IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy

Marta Campagnolo; Renato Zambello; Eduardo Nobile-Orazio; Luana Benedetti; Girolama Alessandra Marfia; Nilo Riva; Francesca Castellani; Mariangela Bianco; Alessandro Salvalaggio; Martina Garnero; Marta Ruiz; Giorgia Mataluni; Raffaella Fazio; Mario Ermani; Chiara Briani

doi:10.1136/jnnp-2017-315736

IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1094-1097. doi: 10.1136/jnnp-2017-315736. Epub 2017 May 13.

Authors

Affiliations

¹ Department of Neurosciences, University of Padova, Padua, Italy.
² Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padua, Italy.
³ Second Neurology, Humanitas Clinical and Research Centre, Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy.
⁴ Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova and IRCCS AOU San Martino-IST, Genoa, Italy.
⁵ Neurology COU, Department of Systems Medicine, University of Tor Vergata, Rome, Italy.
⁶ Department of Neurology, San Raffaele Scientific Institute, Milan, Italy.

PMID: 28501820
DOI: 10.1136/jnnp-2017-315736

No abstract available

Keywords: IgM paraprotein; Waldenstrom’s Macroglobulinemia; antibody; monoclonal gammopathy of undetermined significance (MGUS).; myelin-associated glycoprotein (MAG); neuropathy; rituximab.

Publication types

Letter
Multicenter Study

MeSH terms

Adult
Aged
Aged, 80 and over
Autoantibodies / blood
Female
Humans
Immunoglobulin M / immunology*
Immunologic Factors / therapeutic use*
Male
Middle Aged
Peripheral Nervous System Diseases / blood
Peripheral Nervous System Diseases / etiology*
Retrospective Studies
Rituximab / therapeutic use*
Waldenstrom Macroglobulinemia / blood
Waldenstrom Macroglobulinemia / complications
Waldenstrom Macroglobulinemia / drug therapy*

Substances

Autoantibodies
Immunoglobulin M
Immunologic Factors
Rituximab